Download Chapter 23 Heart Failure

THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
Chapter 23 Heart Failure
John McMurray, Mark Petrie, Karl Swedberg,
Michel Komajda, Stefan Anker, and
Roy Gardner
References
1 Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines
for the diagnosis and treatment of acute and chronic heart
failure 2008: The Task Force for the Diagnosis and Treatment
of Acute and Chronic Heart Failure 2008 of the European
Society of Cardiology. Developed in collaboration with the
Heart Failure Association of the ESC (HFA) and endorsed by
the European Society of Intensive Care Medicine (ESICM). Eur
Heart J 2008; 29: 2388–442.
2 Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005
Guideline Update for the Diagnosis and Management of
Chronic Heart Failure in the Adult: a report of the American
College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Writing Committee to Update the
2001 Guidelines for the Evaluation and Management of Heart
Failure): developed in collaboration with the American College
of Chest Physicians and the International Society for Heart and
Lung Transplantation: endorsed by the Heart Rhythm Society.
Circulation 2005; 112: e154–e235.
3 Solomon SD, Dobson J, Pocock S, et al. Candesartan in Heart
failure: Assessment of Reduction in Mortality and morbidity
(CHARM) Investigators. Influence of nonfatal hospitalization
for heart failure on subsequent mortality in patients with
chronic heart failure. Circulation 2007; 116: 1482–7.
4 Fonarow GC. Epidemiology and risk stratification in acute
heart failure. Am Heart J 2008; 155: 200–7.
5 Gardin JM, Siscovick D, Anton Culver H, et al. Sex, age, and
disease affect echocardiographic left ventricular mass and
systolic function in the free-living elderly: The Cardiovascular
Health Study. Circulation 1995; 91: 1739–48.
6 Kupari M, Lindroos M, Livanainen AM, et al. Congestive heart
failure in old age: prevalence, mechanisms and 4-year prognosis
in the Helsinki Ageing Study. J Intern Med 1997; 241: 387–94.
7 Morgan S, Smith H, Simpson I, et al. Prevalence and clinical
characteristics of left ventricular dysfunction among elderly
patients in general practice setting: cross sectional survey. BMJ
1999; 318: 368–72.
8 Hedberg P, Lonnberg I, Jonasson T, et al. Left ventricular
systolic dysfunction in 75-year-old men and women: a
population-based study. Eur Heart J 2001; 22: 676–83.
9 Nielsen OW, Hilden J, Larsen CT, et al. Cross sectional study
estimating prevalence of heart failure and left ventricular systolic
dysfunction in community patients at risk. Heart 2001; 86: 172–8.
10 Cortina A, Reguero J, Segovia E, et al. Prevalence of heart
failure in Asturias (a region in the north of Spain). Am J
Cardiol 2001; 87: 1417–19.
2nd edition
11 Ceia F, Fonseca C, Mota T, et al. Prevalence of chronic heart
failure in South Western Europe: EPICA study. Eur J Heart Fail
2002; 4: 531–9.
12 Redfield MM, Jacobsen SJ, Burnett JC, Jr., et al. Burden
of systolic and diastolic ventricular dysfunction in the
community: appreciating the scope of the heart failure
epidemic. JAMA 2003; 289: 194–202.
13 Mosterd A, Hoes AW, Bruyne MC, et al. Prevalence of
heart failure and left ventricular dysfunction in the general
population; the Rotterdam Study. Eur Heart J 1999; 20: 447–55.
14 Anguita Sánchez M, Crespo Leiro MG, de Teresa Galván E,
et al. PRICE Study Investigators. Prevalence of heart failure in
the Spanish general population aged over 45 years. The PRICE
Study. Rev Esp Cardiol 2008; 61: 1041–9.
15 Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart
failure: the Framingham Study. J Am Coll Cardiol 1993; 22:
6A–13A.
16 Lloyd-Jones DM, Larson MG, Leip EP, et al. Framingham Heart
Study. Lifetime risk for developing congestive heart failure: the
Framingham Heart Study. Circulation 2002; 106: 3068–72.
17 Bleumink GS, Knetsch AM, Sturkenboom MC, et al.
Quantifying the heart failure epidemic: prevalence, incidence
rate, lifetime risk and prognosis of heart failure. The Rotterdam
Study. Eur Heart J 2004; 25: 1614–19.
18 Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in
the incidence of and survival with heart failure. N Engl J Med
2002; 347: 1397–402.
19 Roger VL, Weston SA, Redfield MM, et al. Trends in heart
failure incidence and survival in a community-based
population. JAMA 2004; 292: 344–50.
20 Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and
prevalence of heart failure in elderly persons, 1994–2003. Arch
Intern Med 2008; 168: 418–24.
21 Stewart S, MacIntyre K, Capewell S, et al. Heart failure and the
aging population: an increasing burden in the 21st century?
Heart 2003; 89: 49–53.
22 Stewart S, MacIntyre K, MacLeod MM, et al. Trends in
hospitalization for heart failure in Scotland, 1990–1996. An
epidemic that has reached its peak? Eur Heart J 2001; 22: 209–17.
23 Schaufelberger M, Swedberg K, Koster M, et al. Decreasing
one-year mortality and hospitalization rates for heart failure
in Sweden; Data from the Swedish Hospital Discharge Registry
1988 to 2000. Eur Heart J 2004; 25: 300–7.
24 Mosterd A, Reitsma JB, Grobbee DE. Angiotensin converting
enzyme inhibition and hospitalisation rates for heart failure in
the Netherlands, 1980 to 1999: the end of an epidemic? Heart
2002; 87: 75–6.
25 Cowie MR, Fox KF, Wood DA, et al. Hospitalization of patients
with heart failure: a population-based study. Eur Heart J 2002;
23: 877–85.
26 Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients
newly admitted to hospital with heart failure: survival trends
in 12 220 index admissions in Leicestershire 1993–2001. Heart
2003; 89: 615–20.
27 Lee DS, Mamdani MM, Austin PC, et al. Trends in heart failure
outcomes and pharmacotherapy: 1992 to 2000. Am J Med 2004;
116: 581–9.
© 2009 The European Society of Cardiology
Camm-Chap-23.indd Sec1:1
7/17/2009 3:45:26 PM
THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
28 Baker DW, Einstadter D, Thomas C, et al. Mortality trends
for 23 505 Medicare patients hospitalized with heart failure in
Northeast Ohio, 1991 to 1997. Am Heart J 2003; 146: 258–64.
29 Fang J, Mensah GA, Croft JB, et al. Heart failure-related
Hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol
2008; 52: 428–34.
30 Guijarro R, San Román CM, Perelló JI, et al. Efficiency Group
of the Internal Medicine Services of Andalusia; Strategic Plan
of the SADEMI (Andalusia Society of Internal Medicine). A
study of hospital discharges for venous thromboembolism in
the south of Spain. An analysis of 19,170 cases from a regional
database from 1998 to 2001. Eur J Intern Med 2005; 16: 279–86.
31 Mosterd A, Hoes AW. Clinical epidemiology of heart failure.
Heart 2007; 93: 1137–46.
32 Stewart S, Horowitz JD. Detecting early clinical deterioration in
chronic heart failure patients post-acute hospitalisation – a critical
component of multidisciplinary, home-based intervention?
Eur J Heart Fail 2002; 4: 345–51.
33 Stewart S, Jenkins A, Buchan S, et al. The current cost of heart
failure to the National Health Service in the UK. Eur J Heart
Fail 2002; 4: 361–71.
34 Murphy NF, Simpson CR, McAlister FA, et al. National
survey of the prevalence, incidence, primary care burden, and
treatment of heart failure in Scotland. Heart 2004; 90: 1129–36.
35 Hobbs FD, Kenkre JE, Roalfe AK, et al. Impact of heart failure
and left ventricular systolic dysfunction on quality of life: a
cross-sectional study comparing common chronic cardiac and
medical disorders and a representative adult population. Eur
Heart J 2002; 23: 1867–76.
36 Cowie MR, Wood DA, Coats AJ, et al. Survival of patients with
a new diagnosis of heart failure: a population based study.
Heart 2000; 83: 505–10.
37 Loehr LR, Rosamond WD, Chang PP, et al. Heart failure
incidence and survival (from the Atherosclerosis Risk in
Communities study). Am J Cardiol 2008; 101: 1016–22.
38 MacIntyre K, Capewell S, Stewart S, et al. Evidence of
improving prognosis in heart failure: trends in case fatality in
66 547 patients hospitalised between 1986 and 1995. Circulation
2000; 102: 1126–31.
39 Stewart S, MacIntyre K, Hole DJ, et al. More 'malignant' than
cancer? Five-year survival following a first admission for heart
failure. Eur J Heart Fail 2001; 3: 315–22.
40 Jhund PS, MacIntyre K, Simpson CR, et al. Long-term trends
in first hospitalization for heart failure and subsequent survival
between 1986 and 2003: a population study of 5.1 million
people. Circulation 2009; 119: 515–23.
41 Ko DT, Alter DA, Austin PC, et al. Life expectancy after
an index hospitalization for patients with heart failure: a
population-based study. Am Heart J 2008; 155: 324–31.
42 Miyagishima K, Hiramitsu S, Kimura H, et al. Long term
prognosis of chronic heart failure. Circulation 2009; 73: 92–9.
43 Mehta PA, Dubrey SW, McIntyre HF, et al. Mode of death
in patients with newly diagnosed heart failure in the general
population. Eur J Heart Fail 2008; 10: 1108–16.
44 Hogg K, Swedberg K, McMurray J. Heart failure with preserved
left ventricular systolic function: epidemiology, clinical
characteristics, and prognosis. J Am Coll Cardiol 2004; 43: 317–27.
2nd edition
45 Thomas MD, Fox KF, Coats AJ, et al. The epidemiological
enigma of heart failure with preserved systolic function.
Eur J Heart Fail 2004; 6: 125–36.
46 Senni M, Redfield MM. Heart failure with preserved systolic
function. A different natural history? J Am Coll Cardiol 2001;
38: 1277–82.
47 Banerjee P, Banerjee T, Khand A, et al. Diastolic heart
failure: neglected or misdiagnosed? J Am Coll Cardiol 2002; 39:
138–41.
48 Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of
congestive heart failure in elderly persons: influence of left
ventricular systolic function. The Cardiovascular Health Study.
Ann Intern Med 2002; 137: 631–9.
49 Lenzen MJ, Scholte op Reimer WJ, Boersma E, et al.
Differences between patients with a preserved and a depressed
left ventricular function: a report from the EuroHeart Failure
Survey. Eur Heart J 2004; 25: 1214–20.
50 Fischer M, Baessler A, Hense HW, et al. Prevalence of left
ventricular diastolic dysfunction in the community. Results
from a Doppler echocardiographic-based survey of a
population sample. Eur Heart J 2003; 24: 320–8.
51 Pedersen F, Raymond I, Mehlsen J, et al. Prevalence of diastolic
dysfunction as a possible cause of dyspnea in the elderly. Am J
Med 2005; 118: 25–31.
52 Badano LP, Albanese MC, Biaggio P, et al. Prevalence, clinical
characteristics, quality of life, and prognosis of patients with
congestive heart failure and isolated left ventricular diastolic
dysfunction. J Am Soc Echocardiogr 2004; 17: 253–61.
53 Abhayaratna WP, Smith WT, Becker NG, et al. Prevalence
of heart failure and systolic ventricular dysfunction in older
Australians: the Canberra Heart Study. Med J Aust 2006; 184:
151–4.
54 Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic
heart failure in the community. JAMA 2006; 296: 2209–16.
55 Massie BM, Carson PE, McMurray JJ, et al. the I-PRESERVE
Investigators. Irbesartan in Patients with Heart Failure and
Preserved Ejection Fraction. N Engl J Med 2008; 359: 2456–67.
56 Wang TJ, Levy D, Benjamin EJ, et al. The epidemiology
of ‘asymptomatic’ left ventricular systolic dysfunction:
implications for screening. Ann Intern Med 2003; 138: 907–16.
57 McDonagh TA, McDonald K, Maisel AS. Screening for
asymptomatic left ventricular dysfunction using B-type
natriuretic Peptide. Congest Heart Fail 2008; 14(4 Suppl.1):
5–8.
58 Pedersen F, Raymond I, Madsen LH, et al. Echocardiographic
indices of left ventricular diastolic dysfunction in 647
individuals with preserved left ventricular systolic function. Eur
J Heart Fail 2004; 6: 439–47.
59 Mendez GF, Cowie MR. The epidemiological features of heart
failure in developing countries: a review of the literature. Int J
Cardiol 2001; 80: 213–19.
60 Agarwal AK, Venugopalan P, Bono D. Prevalence and aetiology
of heart failure in an Arab population. Eur J Heart Fail 2001; 3:
301–305.
61 Bocchi E, Guimarães G, Tarasoutshi F, et al. Cardiomyopathy,
adult valve disease, and heart failure in South America. Heart
2000; 95: 181–9.
© 2009 The European Society of Cardiology
Camm-Chap-23.indd Sec1:2
7/17/2009 3:45:26 PM
THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
62 Marijon E, Ou P, Celermajers DS, et al. Prevalence of
rheumatic heart disease detected by echocardiographic
screening. N Engl J Med 2007; 357: 470–6.
63 Stewart S, Wilkinson D, Hansen C, et al. A predominance of
heart failure in the Heart of Soweto Study cohort: emerging
challenges for urban African communities. Circulation 2008;
118: 2360–7.
64 Velazquez EJ, Lee KL, O’Connor CM, et al. STICH Investigator.
The rationale and design of the Surgical Treatment for
Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg
2007; 134: 1540–7.
65 Levy D, Larson MG, Vasan RS, et al. The progression from
hypertension to congestive heart failure. JAMA 1996; 275:
1557–62.
66 Kostis JB, Davis BR, Cutler J et al. Prevention of heart failure
by antihypertensive drug treatment in older persons with
isolated systolic hypertension. SHEP Cooperative Research
Group. JAMA 1997; 278: 212–16.
67 Lehnart SE, Ackerman MJ, Benson DW, Jr., et al. Inherited
arrhythmias: a National Heart, Lung, and Blood Institute and
Office of Rare Diseases workshop consensus report about
the diagnosis, phenotyping, molecular mechanisms, and
therapeutic approaches for primary cardiomyopathies of gene
mutations affecting ion channel function. Circulation 2007;
116: 2325–45.
68 Kuethe F, Sigusch HH, Hilbig K, et al. Detection of viral
genome in the myocardium: lack of prognostic and functional
relevance in patients with acute dilated cardiomyopathy.
Am Heart J 2007; 153: 850–8.
69 Broder H, Gottlieb RA, Lepor NE. Chemotherapy and
cardiotoxicity. Rev Cardiovasc Med 2008; 9: 75–83.
70 MacDonald MR, Petrie MC, Hawkins NM, et al. Diabetes, left
ventricular systolic dysfunction, and chronic heart failure.
Eur Heart J 2008; 29: 1224–40.
71 Murphy NF, MacIntyre K, Stewart S, et al. Long-term
cardiovascular consequences of obesity: 20-year follow-up
of more than 15 000 middle-aged men and women
(the Renfrew-Paisley study). Eur Heart J 2006; 27:
96–106.
72 Stewart S, Hart CL, Hole DJ, et al. A population-based study of
the long-term risks associated with atrial fibrillation: 20-year
follow-up of the Renfrew/Paisley study. Am J Med 2002; 113:
359–64.
73 Jeong YH, Choi KJ, Song JM, et al. Diagnostic approach and
treatment strategy in tachycardia-induced cardiomyopathy.
Clin Cardiol 2008; 31: 172–8.
74 Shinbane JS, Wood MA, Jensen DN, et al. Tachycardiainduced cardiomyopathy: a review of animal models and
clinical studies. J Am Coll Cardiol 1997; 29: 709–15.
75 Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac
comorbidity increases preventable hospitalizations and
mortality among Medicare beneficiaries with chronic heart
failure. J Am Coll Cardiol 2003; 42: 1226–33.
76 Tang YD, Katz SD. The prevalence of anemia in chronic heart
failure and its impact on the clinical outcomes. Heart Fail Rev
2008; 13: 387–92.
77 Pocock SJ, McMurray JJ, Dobson J, et al. Weight loss and mortality
risk in patients with chronic heart failure in the candesartan in
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
2nd edition
heart failure: assessment of reduction in mortality and morbidity
(CHARM) programme. Eur Heart J 2008; 29: 2641–50.
Macchia A, Monte S, Pellegrini F, et al. Depression worsens
outcomes in elderly patients with heart failure: an analysis of
48,117 patients in a community setting. Eur J Heart Fail 2008;
10: 714–21.
Mookadam F, Calvin AD, Somers VK. Prevalence and
management of central sleep apnea in heart failure patients.
Curr Heart Fail Rep 2008; 5: 233–7.
Petrie CJ, Mark PB, Weir RA. Broken pump or leaky filter?
Renal dysfunction in heart failure a contemporary review.
Int J Cardiol 2008; 128: 154–65.
Lago RM, Singh PP, Nesto RW. Congestive heart failure
and cardiovascular death in patients with prediabetes and
type 2 diabetes given thiazolidinediones: a meta-analysis of
randomised clinical trials. Lancet 2007; 370: 1129–36.
Hudson M, Rahme E, Richard H, et al. Risk of congestive heart
failure with nonsteroidal antiinflammatory drugs and selective
Cyclooxygenase 2 inhibitors: a class effect? Arthritis Rheum
2007; 57: 516–23.
Shlipak MG. Pharmacotherapy for heart failure in patients with
renal insufficiency. Ann Intern Med 2003; 138: 917–24.
Bongartz LG, Cramer MJ, Doevendans PA, et al. The severe
cardiorenal syndrome: ‘Guyton revisited’. Eur Heart J 2005; 26:
11–17.
Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome.
J Am Coll Cardiol 2008; 52: 1527–39.
Damman K, Navis G, Voors AA, et al. Worsening renal
function and prognosis in heart failure: systematic review and
meta-analysis. J Card Fail 2007; 13: 599–608.
Levy WC. Anemia in heart failure: marker or mediator of
adverse prognosis? J Am Coll Cardiol 2008; 51: 577–8.
Murphy NF, McDonald K. Treatment of anaemia in chronic
heart failure – optimal approach still unclear. Eur Heart J 2007;
28: 2185–7.
Groenveld HF, Januzzi JL, Damman K, et al. Anemia and
mortality in heart failure patients a systematic review and metaanalysis. J Am Coll Cardiol 2008; 52: 818–27.
Anker SD, Negassa A, Coats AJ, et al. Prognostic importance
of weight loss in chronic heart failure and the effect of
treatment with angiotensin-converting-enzyme inhibitors: an
observational study. Lancet 2003; 361: 1077–83.
von Haehling S, Lainscak M, Springer J, et al. Cardiac cachexia:
A systematic overview. Pharmacol Ther 2009; 121: 227–52.
Cohn JN, Ferrari R, Sharpe N. Cardiac remodelling –
concepts and clinical implications: a consensus paper from
an international forum on cardiac remodeling. Behalf of an
International Forum on Cardiac Remodeling. J Am Coll Cardiol
2000; 35: 569–82.
Mudd JO, Kass DA. Tackling heart failure in the twenty first
century. Nature 2008; 451: 919–27.
Divakaran V, Mann DL. The emerging role of microRNAs
in cardiac remodeling and heart failure. Circ Res 2008; 103:
1072–83.
Levick SP, Brower GL. Regulation of matrix metalloproteinases
is at the heart of myocardial remodeling. Am J Physiol Heart
Circ Physiol 2008; 295: H1375–H1376.
© 2009 The European Society of Cardiology
Camm-Chap-23.indd Sec1:3
7/17/2009 3:45:26 PM
THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
96 Latini R, Masson S, Staszewsky L, et al. Neurohormonal
modulation in heart failure of ischemic etiology: correlates
with left ventricular remodeling. Curr Heart Fail Rep 2006; 3:
157–63.
97 Mudd JO, Kass DA. Reversing chronic remodeling in heart
failure. Expert Rev Cardiovasc Ther 2007; 5: 585–98.
98 Abrahamsson P, Dobson J, Granger CB, et al. for the CHARM
Investigators. Impact of hospitalization for acute coronary
events on subsequent mortality in patients with chronic heart
failure. Heart J 2009; 30: 338–45.
99 Neubauer S. The failing heart – an engine out of fuel.
N Engl J Med 2007; 356: 1140–51.
100 Bleasdale RA, Frenneaux MP. Cardiac resynchronisation
therapy: when the drugs don't work. Heart 2004; 90: vi2–4.
101 Ashrafian H, Williams L, Frenneaux MP. The pathophysiology
of heart failure: a tale of two old paradigms revisited. Clin Med
2008; 8: 192–7.
102 Elliott P, Andersson B, Arbustini E, et al. Classification of the
cardiomyopathies: a position statement from the European
Society Of Cardiology Working Group on Myocardial and
Pericardial Diseases. Eur Heart J 2008; 29: 270–6.
103 Deo R, MacRae CA. The genetics of cardiomyopathies: what
clinicians should know. Curr Heart Fail Rep 2007; 4: 229–35.
104 Malcom J, Arnold O, Howlett JG, et al. Canadian
Cardiovascular Society. Canadian Cardiovascular Society
Consensus Conference guidelines on heart failure – 2008
update: best practices for the transition of care of heart failure
patients, and the recognition, investigation and treatment of
cardiomyopathies. Can J Cardiol 2008; 24: 21–40.
105 Kitzman DW. Diastolic dysfunction: one piece of the heart
failure with normal ejection fraction puzzle. Circulation 2008;
117: 2044–6.
106 Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose
diastolic heart failure: a consensus statement on the diagnosis
of heart failure with normal left ventricular ejection fraction
by the Heart Failure and Echocardiography Associations of
the European Society of Cardiology. Eur Heart J 2007; 28:
2539–50.
107 Martos R, Baugh J, Ledwidge M, et al. Diastolic heart failure:
evidence of increased myocardial collagen turnover linked to
diastolic dysfunction. Circulation 2007; 115: 888–95.
108 Lam CS, Roger VL, Rodeheffer RJ, et al. Cardiac structure and
ventricular-vascular function in persons with heart failure and
preserved ejection fraction from Olmsted County, Minnesota.
Circulation 2007; 115: 1982–90.
109 Cohen-Solal A, Logeart D, Tartiere JM. ‘Diastolic’ heart
failure, overlooked systolic dysfunction, altered ventriculoarterial coupling or limitation of cardiac reserve? Int J Cardiol
2008; 128: 299–303.
110 Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure –
abnormalities in active relaxation and passive stiffness of the
left ventricle. N Engl J Med 2004; 350: 1953–9.
111 Kushwaha SS, Fallon JT, Fuster V. Restrictive
cardiomyopathy. N Engl J Med 1997; 336: 267–76.
112 Eshaghian S, Kaul S, Shah PK. Cardiac amyloidosis: new
insights into diagnosis and management. Rev Cardiovasc Med
2007; 8: 189–99.
2nd edition
113 Kim JS, Kim HH, Yoon Y. Imaging of pericardial diseases.
Clin Radiol 2007; 62: 626–31.
114 Goldstein JA. Cardiac tamponade, constrictive pericarditis, and
restrictive cardiomyopathy. Curr Probl Cardiol 2004; 29: 503–67.
115 Zile MR, Gaasch WH. Heart failure in aortic stenosis –
improving diagnosis and treatment. N Engl J Med 2003; 348:
1735–6.
116 Borer JS, Truter SL, Gupta A, et al. Heart failure in aortic
regurgitation: the role of primary fibrosis and its cellular and
molecular pathophysiology. Adv Cardiol 2004; 41: 16–24.
117 Mehra MR, Gheorghiade M, Bonow RO. Mitral regurgitation
in chronic heart failure: more questions than answers? Curr
Cardiol Rep 2004; 6: 96–9.
118 Weil J, Eschenhagen T, Hirt S, et al. Preserved Frank-Starling
mechanism in human end stage heart failure. Cardiovasc Res
1998; 37: 541–8.
119 Sandler H, Dodge HT. Left ventricular tension and stress in
man. Circ Res 1963; 13: 91.
120 Opie LH, Commerford PJ, Gersh BJ, et al. Controversies in
ventricular remodelling. Lancet 2006; 367: 356–67.
121 Spann JF, Buccino RA, Sonnenblick EH, et al. Contractile
state of cardiac muscle obtained from cats with experimentally
produced ventricular hypertrophy and heart failure. Circ Res
1967; 21: 341–54.
122 Nishida K, Yamaguchi Otsu K, et al. Crosstalk between autophagy
and apoptosis in heart disease. Circ Res 2008; 103: 343–51.
123 Francis GS, Cohn JN. Heart failure: mechanisms of cardiac
and vascular dysfunction and the rationale for pharmacologic
intervention. FASEB J 1990; 4: 3068–75.
124 Harris P. Biology of cardiac failure. Eur Heart J 1982;
3(Suppl.D): 5–10.
125 de Sa DD, Chen HH. The role of natriuretic peptides in heart
failure. Curr Cardiol Rep 2008; 10: 182–9.
126 Bunton DC, Petrie MC, Hillier C, et al. The clinical relevance
of adrenomedullin: a promising profile? Pharmacol Ther 2004;
103: 179–201.
127 Hogg K, McMurray J. Neurohumoral pathways in heart
failure with preserved systolic function. Prog Cardiovasc Dis
2005; 47: 357–66.
128 Braunwald E, Harrison DC, Chidsey CA. The heart as an
endocrine organ. Am J Med 1964; 36: 1–4.
129 Francis GS, Cohn JN. The autonomic nervous system in
congestive heart failure. Annu Rev Med 1986; 37: 235–47.
130 Tsutamoto T, Nishiyama K, Sakai H, et al. Transcardiac
increase in norepinephrine and prognosis in patients with
chronic heart failure. Eur J Heart Fail 2008; 10: 1208–14.
131 Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine
as a guide to prognosis in patients with chronic congestive
heart failure. N Engl J Med 1984; 311: 819–23.
132 Unger T, Li J. The role of the renin-angiotensin-aldosterone
system in heart failure. J Renin Angiotensin Aldosterone Syst
2004; 5(Suppl.1): S7–S10.
133 Epelman S, Tang WH, Chen SY, et al. Detection of soluble
angiotensin-converting enzyme 2 in heart failure: insights
into the endogenous counter-regulatory pathway of the
renin-angiotensin-aldosterone system. J Am Coll Cardiol
2008; 52: 750–4.
© 2009 The European Society of Cardiology
Camm-Chap-23.indd Sec1:4
7/17/2009 3:45:26 PM
THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
134 Levine TB, Cohn JN, Vrobel T, Franciosa JA. High renin in
heart failure: a manifestation of hyponatremia. Trans Assoc
Am Physicians 1979; 92: 203–7.
135 Pitt B. Aldosterone blockade in patients with chronic heart
failure. Cardiol Clin 2008; 26: 15–21.
136 Batenburg WW, Jan Danser AH. The (pro)renin receptor:
a new addition to the renin-angiotensin system? Eur J
Pharmacol 2008; 585: 320–4.
137 Goldsmith SR, Gheorghiade M. Vasopressin antagonism in
heart failure. J Am Coll Cardiol 2005; 46: 1785–91.
138 Finley JJ, 4th, Konstam MA, Udelson JE. Arginine
vasopressin antagonists for the treatment of heart failure and
hyponatremia. Circulation 2008; 118: 410–21.
139 Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol
2007; 50: 2357–68.
140 Richards AM. Natriuretic peptides: update on Peptide release,
bioactivity, and clinical use. Hypertension 2007; 50: 25–30.
141 Lee CY, Burnett JC, Jr. Natriuretic peptides and therapeutic
applications. Heart Fail Rev 2007; 12: 131–42.
142 Akashi YJ, Springer J, Lainscak M, et al. Atrial natriuretic
peptide and related peptides. Clin Chem Lab Med 2007; 45:
1259–67.
143 Chandrasekaran B, Dar O, McDonagh T. The role of apelin
in cardiovascular function and heart failure. Eur J Heart Fail
2008; 10: 725–32.
144 Tang WH, Francis GS. Exploring new drugs for heart failure:
the case of urocortin. Eur Heart J 2007; 28: 2561–2.
145 Fisher C, MacLean M, Morecroft I, et al. Is the pregnancy
hormone relaxin also a vasodilator peptide secreted by the
heart? Circulation 2002; 106: 292–5.
146 Teerlink JR, Metra M, Felker GM, et al. Relaxin for the
treatment of patients with acute heart failure (Pre-RELAXAHF): a multicentre, randomised, placebo-controlled,
parallel-group, dose-finding phase IIb study. Lancet 2009; 373:
1429–39.
147 Drexler H, Hayoz D, Munzel T, et al. Endothelial function
in chronic congestive heart failure. Am J Cardiol 1992; 69:
1596–601.
148 Hambrecht R, Adams V, Gielen S, et al. Exercise intolerance in
patients with chronic heart failure and increased expression of
inducible nitric oxide synthase in the skeletal muscle.
J Am Coll Cardiol 1999; 33: 174–9.
149 Cowburn PJ, Cleland JG. Endothelin antagonists for chronic
heart failure: do they have a role? Eur Heart J 2001; 22: 1772–84.
150 McMurray J, Chopra M, Abdullah I, et al. Evidence of
oxidative stress in chronic heart failure in humans. Eur Heart J
1993; 14: 1493–8.
151 Grieve DJ, Shah AM. Oxidative stress in heart failure. More
than just damage. Eur Heart J 2003; 24: 2161–3.
152 Landmesser U, Spiekermann S, Dikalov S, et al. Vascular
oxidative stress and endothelial dysfunction in patients with
chronic heart failure: role of xanthine-oxidase and extracellular
superoxide dismutase. Circulation 2002; 106: 3073–8.
153 Berry C, Hamilton CA, Brosnan MJ, et al. Investigation into
the sources of superoxide in human blood vessels: angiotensin
II increases superoxide production in human internal
mammary arteries. Circulation 2000; 101: 2206–12.
2nd edition
154 Doehner W, Springer J, Landmesser U, et al. Uric acid in
chronic heart failure – current pathophysiological concepts.
Eur J Heart Fail 2008; 10: 1269–70.
155 Hare JM, Mangal B, Brown J, et al. OPT-CHF Investigators.
Impact of oxypurinol in patients with symptomatic heart
failure. Results of theOPT-CHF study. J Am Coll Cardiol 2008;
51: 2301–9.
156 Keith ME, Jeejeebhoy KN, Langer A, et al. A controlled clinical
trial of vitamin E supplementation in patients with congestive
heart failure. Am J Clin Nutr 2001; 73: 219–24.
157 Heymans S, Hirsch E, Anker S, et al. Inflammation as a
therapeutic target in heart failure? A Scientific Statement
From the Translational Research Committee of the Heart
Failure Association of the European Society of Cardiology. Eur
J Heart Failure 2009; 11: 119–29.
158 Rauchhaus M, Coats AJ, Anker SD. The endotoxin–
lipoprotein hypothesis. Lancet 2000; 356: 930–3.
159 Mann DL, McMurray JJ, Packer M, et al. Targeted
anticytokine therapy in patients with chronic heart failure:
results of the Randomized Etanercept Worldwide Evaluation
(RENEWAL). Circulation 2004; 109: 1594–602.
160 Chung ES, Packer M, Lo KH, et al. Anti-TNF Therapy Against
Congestive Heart Failure Investigators. Randomized, doubleblind, placebo-controlled, pilot trial of infliximab, a chimeric
monoclonal antibody to tumor necrosis factor-alpha, in
patients with moderate-to-severe heart failure: results of
the anti-TNF Therapy Against Congestive Heart Failure
(ATTACH) trial. Circulation 2003; 107: 3133–40.
161 Mancini DM. Pulmonary factors limiting exercise capacity in
patients with heart failure. Prog Cardiovasc Dis 1995; 37: 347.
162 Piepoli M, Ponikowski P, Clark AL. A neural link to explain
the ‘muscle hypothesis’ of exercise intolerance in chronic
heart failure. Am Heart J 1999; 137: 1050–6.
163 Geltman EM. Mild heart failure: diagnosis and treatment. Am
Heart J 1989; 118: 1277.
164 Clark AL. Origin of symptoms in chronic heart failure. Heart
2006; 92: 12–16.
165 Davie AP, Francis CM, Caruana L, et al. Assessing diagnosis
in heart failure: which features are any use? Q J Med 1997; 90:
335–9.
166 Madhok V, Falk G, Rogers A, et al. The accuracy of symptoms,
signs and diagnostic tests in the diagnosis of left ventricular
dysfunction in primary care: a diagnostic accuracy systematic
review. BMC Fam Pract 2008; 9: 56.
167 Anselm AH, Gauthier N, Beanlands RS, et al. Sleep apnea in
chronic heart failure. Curr Opin Cardiol 2008; 23: 121–6.
168 Criteria Committee, New-York Association, Inc. Diseases of
the Heart and Blood Vessels. Nomenclature and Criteria for
Diagnosis, 6th edn., 1964. Boston: Little Brown & Co., p. 114.
169 Marantz PR, Tobin JN, Wassertheil-Smoller S, et al. The
relationship by clinical criteria. Circulation 1988; 77: 607–12.
170 Khot UN, Jia G, Moliterno DJ, et al. Prognostic importance
of physical examination for heart failure in non-ST-elevation
acute coronary syndromes: the enduring value of Killip
classification. JAMA 2003; 290: 2174–81.
171 Rector TS, Cohn JN. Assessment of patient outcome with the
Minnesota Living with Heart Failure questionnaire: reliability
© 2009 The European Society of Cardiology
Camm-Chap-23.indd Sec1:5
7/17/2009 3:45:26 PM
THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
172
173
174
175
176
177
178
179
180
181
182
183
184
185
and validity during a randomised, double-blind, placebocontrolled trial of pimobendan. Pimobendan Multicenter
Research Group. Am Heart J 1992; 124: 1017–25.
Spertus JA, Jones PG, Kim J, et al. Validity, reliability,
and responsiveness of the Kansas City Cardiomyopathy
Questionnaire in anemic heart failure patients. Qual Life Res
2008; 17: 291–8.
Spiteri MA, Cook DG, Clarke SW. Reliability of eliciting
physical signs in examination of the chest. Lancet 1988; 1:
873–5.
Butman SM, Ewy GA, Standen JR, et al. Bedside
cardiovascular examination in patients with severe chronic
heart failure: importance of rest or inducible jugular venous
distension. J Am Coll Cardiol 1993; 22: 968–74.
Lok CE, Morgan CD, Ranganathan N. The accuracy and
interobserver agreement in detecting the ‘gallop sounds’ by
cardiac auscultation. Chest 1998; 114: 1283–8.
Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic
importance of elevated jugular venous pressure and a third
heart sound in patients with heart failure. N Engl J Med 2001;
345: 574–81.
Rihal CS, Davis KB, Kennedy JW, et al. The utility of clinical,
electrocardiographic and roentgenographic variables in the
prediction of left ventricular function. Am J Cardiol 1995; 75:
220–3.
Clark AL, Goode K, Cleland JG. The prevalence and incidence
of left bundle branch block in ambulant patients with chronic
heart failure. Eur J Heart Fail 2008; 10: 696–702.
Hawkins NM, Wang D, McMurray JJ, et al. CHARM
Investigators and Committees. Prevalence and prognostic impact
of bundle branch block in patients with heart failure: evidence
from the CHARM programme. Eur J Heart Fail 2007; 9: 510–17.
Gillespie ND, McNeill G, Pringle T, et al. Cross sectional
study of contribution of clinical assessment and simple
cardiac investigations to diagnosis of left ventricular systolic
dysfunction in patients admitted with acute dyspnoea. BMJ
1997; 314: 936–40.
Petrie MC, McMurray JJV. It cannot be cardiac failure because
the heart is not enlarged on the chest X-ray. Eur J Heart Fail
2003; 5: 117–19.
Chakko S, Woska D, Martinez H, et al. Clinical, radiographic
and hemodynamic correlations in chronic congestive heart
failure: conflicting results may lead to inappropriate care. Am
J Med 1991; 90: 353–9.
Peacock WF 4th, De Marco T, Fonarow GC, et al. ADHERE
Investigators. Cardiac troponin and outcome in acute heart
failure. N Engl J Med 2008; 358: 2117–26.
Tang WH, Francis GS, Morrow DA, et al. National Academy
of Clinical Biochemistry Laboratory Medicine. National
Academy of Clinical Biochemistry Laboratory Medicine
practice guidelines: Clinical utilization of cardiac biomarker
testing in heart failure. Circulation 2007; 116: e99–e109.
Gheorghiade M, Konstam MA, Burnett JC Jr., et al. Efficacy
of Vasopressin Antagonism in Heart Failure Outcome Study
With Tolvaptan(EVEREST) Investigators. Short-term clinical
effects of tolvaptan, an oral vasopressin antagonist, in patients
hospitalized for heart failure: the EVEREST Clinical Status
Trials. JAMA 2007; 297: 1332–43.
2nd edition
186 Juurlink DN, Mamdani MM, Lee DS, et al. Rates of
hyperkalaemia after publication of the Randomized Aldactone
Evaluation Study. N Engl J Med 2004; 351: 543–551.
187 Allen LA, Felker GM, Pocock S, et al. Liver function
abnormalities and outcome in patients with chronic
heart failure: data from the Candesartan in Heart Failure:
Assessment of Reduction in Mortality and Morbidity
(CHARM) program. Eur J Heart Fail 2009; 11: 170–7.
188 Felker GM, Allen LA, Pocock SJ, et al. CHARM Investigators.
Red cell distribution width as a novel prognostic marker in
heart failure:data from the CHARM Program and the Duke
Databank. J Am Coll Cardiol 2007; 50: 40–7.
189 Maisel A, Mueller C, Adams K, Jr., et al. State of the art: using
natriuretic peptide levels in clinical practice. Eur J Heart Fail
2008; 10: 824–39.
190 Vajan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic
peptides for community screening for left ventricular
hypertrophy and systolic dysfunction. The Framingham Heart
Study. JAMA 2002; 288: 1252–9.
191 Cleland, JG, Swedberg, K, Follath, F et al. The Euro Heart
Failure Survey Progamme: a survey on the quality of care
among patients with heart failure in Europe. Part I: patient
characteristics and diagnosis. Eur Heart J 2003; 24: 442–63.
192 Remme WJ, McMurray JJ, Hobbs FD, et al. SHAPE Study
Group. Awareness and perception of heart failure among
European cardiologists, internists, geriatricians, and primary
care physicians. Eur Heart J 2008; 29: 1739–52.
193 Otterstad JE, Froeland G, Sutton STM, et al. Accuracy and
reproducibility of biplane two-dimensional echocardiographic
measurements of left ventricular dimensions and function.
Eur Heart J 1997; 18: 507–13.
194 Nagueh SF, Appleton CP, Gillebert TC, et al.
Recommendations for the evaluation of left ventricular
diastolic function by echocardiography. J Am Soc Echocardiogr
2009; 22: 107–33.
195 Whalley GA, Gamble GD, Dini FL, et al. Meta-Analysis
Research Group in Echocardiography (MeRGE)
Collaborators. Individual patient meta-analyses of restrictive
diastolic filling pattern and mortality in patients post acute
myocardial infarction and in patients with chronic heart
failure. Int J Cardiol 2007; 122: 207–15.
196 Sicari R, Nihoyannopoulos P, Evangelista A, et al. Stress
Echocardiography Expert Consensus Statement – Executive
Summary: European Association of Echocardiography (EAE)
(a registered branch of the ESC). Eur Heart J 2009; 30: 278–89.
197 Assomull RG, Pennell DJ, Prasad SK. Cardiovascular magnetic
resonance in the evaluation of heart failure. Heart 2007; 93:
985–92.
198 Task Force of the Italian Working Group on Cardiac
Rehabilitation and Prevention (Gruppo Italiano di
Cardiologia Riabilitativa e Prevenzione,GICR); Working
Group on Cardiac Rehabilitation and Exercise Physiology
of the European Society of Cardiology, Piepoli MF, Corrà
U, et al. Statement on cardiopulmonary exercise testing
in chronic heart failure due toleft ventricular dysfunction:
recommendations for performance andinterpretation Part II:
How to perform cardiopulmonary exercise testing in chronic
heart failure. Eur J Cardiovasc Prev Rehabil 2006; 13: 300–11.
© 2009 The European Society of Cardiology
Camm-Chap-23.indd Sec1:6
7/17/2009 3:45:27 PM
THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
199 Gardner RS, McDonagh TA, MacDonald M, et al. Who needs
a heart transplant? Eur Heart J 2006; 27: 770–2.
200 Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and
chronic obstructive pumonary disease: diagnostic pitfalls and
epidemiology. Eur J Heart Fail 2009; 11: 130–9.
201 Binanay C, Califf RM, Hasselblad V, et al. ESCAPE Investigators
and ESCAPE Study Coordinators. Evaluation study of
congestive heart failure and pulmonary artery catheterization
effectiveness: the ESCAPE trial. JAMA 2005; 294: 1625–33.
202 Cleland JC, Pennell DJ, Ray SG, et al. Myocardial viability as a
determinant of the ejection fraction response to carvedilol in
patients with heart failure (CHRISTMAS trial): randomised
controlled trial. Lancet 2003; 362: 14–21.
203 Cooper LT, Baughman KL, Feldman AM, et al. The role of
endomyocardial biopsy in the management of cardiovascular
disease: a scientific statement from the American Heart
Association, the American College of Cardiology, and the
European Society of Cardiology Endorsed by the Heart Failure
Society of America and the Heart Failure Association of the
European Society of Cardiology. Eur Heart J 2007; 28: 3076–93.
204 Nohria A, Tsang SW, Fang JC, et al. Clinical assessment
identifies hemodynamic profiles that predict outcomes in
patients admitted with heart failure. J Am Coll Cardiol 2003;
41: 1797–804.
205 Pope CA 3rd, Renlund DG, Kfoury AG, et al. Relation of
heart failure hospitalization to exposure to fine particulate air
pollution. Am J Cardiol 2008; 102: 1230–4.
206 Stewart S, McMurray JJ. Chilling findings: the need for winter
vigilance in heart failure. J Card Fail 2006; 12: 120–1.
207 Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation
and risk of clinical events in chronic heart failure with and
without left ventricular systolic dysfunction: results from
the Candesartan in Heart failure – Assessment of Reduction
in Mortality and morbidity (CHARM) program. J Am Coll
Cardiol 2006; 47: 1997–2004.
208 Rivero-Ayerza M, Scholte Op Reimer W, Lenzen M, et al. Newonset atrial fibrillation is an independent predictor of in-hospital
mortality in hospitalized heart failure patients: results of the
EuroHeart Failure Survey. Eur Heart J 2008; 29: 1618–24.
209 Levy WC, Mozaffarian D, Linker DT, et al. The Seattle
Heart Failure Model: prediction of survival in heart failure.
Circulation 2006; 113: 1424–33.
210 Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality
and morbidity in patients with chronic heart failure. Eur Heart
J 2006; 27: 65–75.
211 Latini R, Masson S, Anand I, et al. The comparative
prognostic value of plasma neurohormones at baseline in
patients with heart failure enrolled in Val-HeFT. Eur Heart J
2004; 25: 292–9.
212 Masson S, Latini R, Anand IS; on behalf of the Val-HeFT
Investigators. Prognostic value of changes in N-terminal
pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart
Failure Trial). J Am Coll Cardiol 2008; 52: 997–1003.
213 Goebel JA, Van Bakel AB. Rational use of diuretics in acute
decompensated heart failure. Curr Heart Fail Rep 2008; 5: 153–62.
214 Faris R, Flather M, Purcell H, et al. Current evidence
supporting the role of diuretics in heart failure: a meta analysis
of randomised controlled trials. Int J Cardiol 2002; 82: 149–58.
2nd edition
215 Rosenberg J, Gustafsson F, Galatius S, et al. Combination
therapy with metolazone and loop diuretics in outpatients
with refractory heart failure: an observational study and review
of the literature. Cardiovasc Drugs Ther 2005; 19: 301–6.
216 Iyengar S, Abraham WT. Diuretic resistance in heart failure.
Curr Heart Fail Rep 2006; 3: 41–5.
217 Costanzo MR. Ultrafiltration in the management of heart
failure. Curr Opin Crit Care 2008; 14: 524–30.
218 Pitt B, Zannad F, Remme WJ, et al. The effect of
spironolactone on morbidity and mortality in patients with
severe heart failure. Randomized Aldactone Evaluation Study
Investigators. N Engl J Med 1999; 341: 709–17.
219 McMurray J, Cohen-Solal A, Dietz R, et al. Practical
recommendations for the use of ACE inhibitors, betablockers, aldosterone antagonists and angiotensin receptor
blockers in heart failure: putting guidelines into practice. Eur J
Heart Fail 2005; 7: 710–21.
220 Effects of enalapril on mortality in severe congestive heart
failure. Results of the Cooperative North Scandinavian
Enalapril Survival Study (CONSENSUS). The CONSENSUS
Trial Study Group. N Engl J Med 1987; 316: 1429–35.
221 Effect of enalapril on survival in patients with reduced left
ventricular ejection fractions and congestive heart failure. The
SOLVD Investigators. N Engl J Med 1991; 325: 293–302.
222 Flather MD, Yusuf S, K ber L, et al. Long-term ACE-inhibitor
therapy in patients with heart failure or left-ventricular
dysfunction: a systematic overview of data from individual
patients. ACE-Inhibitor Myocardial Infarction Collaborative
Group. Lancet 2000; 355: 1575–81.
223 Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators
and Committees. Effects of candesartan in patients with chronic
heart failure and reduced left-ventricular systolic function
intolerant to angiotensin-converting-enzyme inhibitors: the
CHARM-Alternative trial. Lancet. 2003; 362: 772–6.
224 Maggioni AP, Anand I, Gottlieb SO, et al. Val-HeFT
Investigators (Valsartan Heart Failure Trial). Effects of
valsartan on morbidity and mortality in patients with
heart failure not receiving angiotensin-converting enzyme
inhibitors. J Am Coll Cardiol 2002; 40: 1414–21.
225 Cohn JN, Tognoni G; Valsartan Heart Failure Trial
Investigators. A randomized trial of the angiotensin-receptor
blocker valsartan in chronic heart failure. N Engl J Med 2001;
345: 1667–75.
226 McMurray JJ, Ostergren J, Swedberg K, et al. CHARM
Investigators and Committees. Effects of candesartan in
patients with chronic heart failure and reduced left-ventricular
systolic function taking angiotensin-converting-enzyme
inhibitors: the CHARM-Added trial. Lancet 2003; 362:
767–71.
227 McKelvie RS, Yusuf S, Pericak D, et al. Comparison of
candesartan, enalapril, and their combination in congestive
heart failure: randomized evaluation of strategies for left
ventricular dysfunction (RESOLVD) pilot study. The RESOLVD
Pilot Study Investigators. Circulation 1999; 100: 1056–64.
228 McKelvie RS, Rouleau JL, White M, et al. Comparative
impact of enalapril, candesartan or metoprolol alone or in
combination on ventricular remodelling in patients with
congestive heart failure. Eur Heart J 2003; 24: 1727–34.
© 2009 The European Society of Cardiology
Camm-Chap-23.indd Sec1:7
7/17/2009 3:45:27 PM
THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
229 Weir RA, McMurray JJ, Puu M, et al. CHARM Investigators.
Efficacy and tolerability of adding an angiotensin receptor
blocker in patients with heart failure already receiving an
angiotensin-converting inhibitor plus aldosterone antagonist,
with or without a beta blocker. Findings from the Candesartan
in Heart failure: Assessment of Reduction in Mortality and
morbidity (CHARM)-Added trial. Eur J Heart Fail 2008; 10:
157–63.
230 Desai AS, Swedberg K, McMurray JJ, et al. CHARM Program
Investigators. Incidence and predictors of hyperkalemia
in patients with heart failure: an analysis of the CHARM
Program. J Am Coll Cardiol 2007; 50: 1959–66.
231 Juurlink DN, Mamdani MM, Lee DS, et al. Rates of
hyperkalemia after publication of the Randomized Aldactone
Evaluation Study. N Engl J Med 2004; 351: 543–51.
232 The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a
randomised trial. Lancet 1999; 353: 9–13.
233 Effect of metoprolol CR/XL in chronic heart failure: Metoprolol
CR/XL Randomised Intervention Trial in Congestive Heart
Failure (MERIT-HF). Lancet 1999; 353: 2001–7.
234 Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects
of controlled-release metoprolol on total mortality,
hospitalizations, and well-being in patients with heart failure:
the Metoprolol CR/XL Randomized Intervention Trial in
congestive heart failure (MERIT-HF). MERIT-HF Study
Group. JAMA 2000; 283: 1295–302.
235 Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol
on morbidity and mortality in patients with chronic heart
failure. U.S. Carvedilol Heart Failure Study Group. N Engl J
Med 1996; 334: 1349–55.
236 Packer M, Coats AJ, Fowler MB, et al. Carvedilol Prospective
Randomized Cumulative Survival Study Group. Effect of
carvedilol on survival in severe chronic heart failure.
N Engl J Med 2001; 344: 1651–8.
237 Packer M, Fowler MB, Roecker EB, et al. Carvedilol
Prospective Randomized Cumulative Survival
(COPERNICUS) Study Group. Effect of carvedilol on the
morbidity of patients with severe chronic heart failure: results
of the carvedilol prospective randomized cumulative survival
(COPERNICUS) study. Circulation 2002; 106: 2194–9.
238 Flather MD, Shibata MC, Coats AJ, et al. SENIORS
Investigators. Randomized trial to determine the effect of
nebivolol on mortality and cardiovascular hospital admission
in elderly patients with heart failure (SENIORS). Eur Heart J
2005; 26: 215–25.
239 Poole-Wilson PA, Swedberg K, Cleland JG, et al. Carvedilol
Or Metoprolol European Trial Investigators. Comparison of
carvedilol and metoprolol on clinical outcomes in patients
with chronic heart failure in the Carvedilol Or Metoprolol
European Trial (COMET): randomised controlled trial.
Lancet 2003; 362: 7–13.
240 Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute
Myocardial Infarction Heart Failure Efficacy and Survival
Study Investigators. Eplerenone, a selective aldosterone
blocker, in patients with left ventricular dysfunction after
myocardial infarction. N Engl J Med 2003; 348: 1309–21.
241 Hood WB, Jr., Dans AL, Guyatt GH, et al. Digitalis for
treatment of congestive heart failure in patients in sinus
242
243
244
245
246
247
248
249
250
251
252
253
254
255
2nd edition
rhythm: a systematic review and meta-analysis. J Card Fail
2004; 10: 155–64.
The effect of digoxin on mortality and morbidity in patients
with heart failure. The Digitalis Investigation Group. N Engl J
Med 1997; 336: 525–33.
Rathore SS, Curtis JP, Wang Y, et al. Association of serum
digoxin concentration and outcomes in patients with heart
failure. JAMA 2003; 289: 871–8.
Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator
therapy on mortality in chronic congestive heart failure.
Results of a Veterans Administration Cooperative Study. N
Engl J Med 1986; 314: 1547–52.
Cohn JN, Johnson G, Ziesche S, et al. A comparison of
enalapril with hydralazine-isosorbide dinitrate in the
treatment of chronic congestive heart failure. N Engl J Med
1991; 325: 303–10.
Taylor AL, Ziesche S, Yancy C, et al. African-American
Heart Failure Trial Investigators. Combination of isosorbide
dinitrate and hydralazine in blacks with heart failure. N Engl J
Med 2004; 351: 2049–57.
GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty
acids in patients with chronic heart failure (the GISSI-HF
trial): a randomised, double-blind, placebo-controlled trial.
Lancet 2008; 372: 1223–30.
Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine
on morbidity and mortality in severe chronic heart failure.
Prospective Randomized Amlodipine Survival Evaluation
Study Group. N Engl J Med 1996; 335: 1107–14.
Dorszewski A, Göhmann E, Dorsźewski B, et al. Vasodilation
by urapidil in the treatment of chronic congestive heart failure
in addition to angiotensin-converting enzyme inhibitors is not
beneficial: results of a placebo-controlled, double-blind study.
J Card Fail 1997; 3: 91–6.
Einhorn PT, Davis BR, Massie BM, et al. ALLHAT
Collaborative Research Group. The Antihypertensive and
Lipid Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT) Heart Failure Validation Study: diagnosis and
prognosis. Am Heart J 2007; 153: 42–53.
Packer M, McMurray J, Massie BM, et al. Clinical effects of
endothelin receptor antagonism with bosentan in patients
with severe chronic heart failure: results of a pilot study. J
Card Fail 2005; 11: 12–20.
Mann DL, McMurray JJ, Packer M, et al. Targeted
anticytokine therapy in patients with chronic heart failure:
results of the Randomized Etanercept Worldwide Evaluation
(RENEWAL). Circulation 2004; 109: 1594–602.
Cohn JN, Goldstein SO, Greenberg BH, et al. A dosedependent increase in mortality with vesnarinone among
patients with severe heart failure. Vesnarinone Trial
Investigators. N Engl J Med 1998; 339: 1810–16.
Cohn JN, Pfeffer MA, Rouleau J, et al. MOXCON
Investigators. Adverse mortality effect of central sympathetic
inhibition with sustained-release moxonidine in patients with
heart failure (MOXCON). Eur J Heart Fail 2003; 5: 659–67.
van Veldhuisen DJ, Poole-Wilson PA. The underreporting
of results and possible mechanisms of ‘negative’ drug trials
in patients with chronic heart failure. Int J Cardiol 2001; 80:
19–27.
© 2009 The European Society of Cardiology
Camm-Chap-23.indd Sec1:8
7/17/2009 3:45:27 PM
THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
256 Packer M, Carver JR, Rodeheffe RJ, et al. Effect of oral
milrinone on mortality in severe chronic heart failure.
The PROMISE Study Research Group. N Engl J Med 1991;
325: 1468–75.
257 Køber L, Torp-Pedersen C, McMurray JJ, et al. Dronedarone
Study Group. Increased mortality after dronedarone therapy
for severe heart failure. N Engl J Med 2008; 358: 2678–87.
258 Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group.
Rosuvastatin in older patients with systolic heart failure. N
Engl J Med 2007; 357: 2248–61.
259 Gissi-Hf Investigators. Effect of rosuvastatin in patients with
chronic heart failure (the GISSI-HF trial): a randomised, doubleblind, placebo-controlled trial. Lancet 2008; 372: 1231–9.
260 Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone
evaluated for cardiovascular outcomes in oral agent
combination therapy for type 2 diabetes (RECORD): a
multicentre, randomised, open-label trial. Lancet 2009; Jun 5.
[Epub ahead of print.]
261 Sochalski J, Jaarsma T, Krumholz HM, et al. What works in
chronic care management: the case of heart failure. Health Aff
(Millwood) 2009; 28: 179–89.
262 Jaarsma T, van der Wal MH, Lesman-Leegte I, et al.
Coordinating Study Evaluating Outcomes of Advising and
Counseling in Heart Failure (COACH) Investigators. Effect
of moderate or intensive disease management program on
outcome in patients with heart failure: Coordinating Study
Evaluating Outcomes of Advising and Counseling in Heart
Failure (COACH). Arch Intern Med 2008; 168: 316–24.
263 Hauptman PJ, Rich MW, Heidenreich PA, et al. Heart Failure
Society of America. The heart failure clinic: a consensus
statement of the Heart Failure Society of America. J Card Fail
2008; 14: 801–15.
264 Clark RA, Inglis SC, McAlister FA, et al. Telemonitoring or
structured telephone support programmes for patients with
chronic heart failure: systematic review and meta-analysis.
BMJ 2007; 334: 942.
265 Bourge RC, Abraham WT, Adamson PB, et al. COMPASS-HF
Study Group. Randomized controlled trial of an implantable
continuous hemodynamic monitor in patients with advanced
heart failure: the COMPASS-HF study. J Am Coll Cardiol
2008; 51: 1073–9.
266 Edwardson SR. Patient education in heart failure. Heart Lung
2007; 36: 244–52.
267 Granger BB, Swedberg K, Ekman I, et al. CHARM
investigators. Adherence to candesartan and placebo and
outcomes in chronic heart failure in the CHARM programme:
double-blind, randomised, controlled clinical trial. Lancet
2005; 366: 2005–11.
268 O’Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety
of exercise training in patients with chronic heart failure:
HF-ACTION randomized controlled trail. JAMA 2009; 301:
1439–50.
269 Flynn KE, Piña IL, Whellan DJ, et al. Effects of exercise
training on health status in patients with chronic heart failure:
HF-ACTION randomized controlled trail. JAMA 2009; 301:
1451–9.
270 Guazzi M. Sildenafil and phosphodiesterase-5 inhibitors for
heart failure. Curr Heart Fail Rep 2008; 5: 110–14.
2nd edition
271 Fox K, Ford I, Steg PG, et al. on behalf of the BEAUTIFUL
Investigators. Ivabradine for patients with stable coronary
artery disease and left-ventricular systolic dysfunction
(BEAUTIFUL): a randomised, double-blind, placebocontrolled trial. Lancet 2008; 372: 807–16.
272 Roy D, Talajic M, Nattel S, et al. Atrial Fibrillation and
Congestive Heart Failure Investigators. Rhythm control versus
rate control for atrial fibrillation and heart failure. N Engl J
Med 2008; 358: 2667–77.
273 Khan MN, Jaïs P, Cummings J, et al. PABA-CHF Investigators.
Pulmonary-vein isolation for atrial fibrillation in patients with
heart failure. N Engl J Med 2008; 359: 1778–85.
274 Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC
2006 guidelines for management of patients with ventricular
arrhythmias and the prevention of sudden cardiac death:
a report of the American College of Cardiology/American
Heart Association Task Force and the European Society of
Cardiology Committee for Practice Guidelines (Writing
Committee to Develop Guidelines for Management of
Patients With Ventricular Arrhythmias and the Prevention of
Sudden Cardiac Death). Developed in collaboration with the
European Heart Rhythm Association and the Heart Rhythm
Society. Europace 2006; 8: 746–837.
275 Newman CM, Price A, Davies DW. Amiodarone and the thyroid:
a practical guide to the management of thyroid dysfunction
induced by amiodarone therapy. Heart 1998; 79: 121–7.
276 Riegger GA, Haeske W, Kraus C, et al. Contribution of the
renin-angiotensin-aldosterone system to development of
tolerance and fluid retention in chronic congestive heart failure
during prazosin treatment. Am J Cardiol 1987; 59: 906–10.
277 van Veldhuisen DJ, McMurray JJ; RED-HF Executive
Committee. Are erythropoietin stimulating proteins safe and
efficacious in heart failure? Why we need an adequately powered
randomised outcome trial. Eur J Heart Fail 2007; 9: 110–12.
278 O’Connor CM, Jiang W, Kuchibhatla M, et al. Antidepressant
use, depression, and survival in patients with heart failure.
Arch Intern Med 2008; 168: 2232–7.
279 Cardinale D, Colombo A, Cipolla CM. Prevention and
treatment of cardiomyopathy and heart failure in patients
receiving cancer chemotherapy. Curr Treat Options Cardiovasc
Med 2008; 10: 486–95.
280 Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic
Defibrillator Implantation Trial II Investigators. Prophylactic
implantation of a defibrillator in patients with myocardial
infarction and reduced ejection fraction. N Engl J Med 2002;
346: 877–83.
281 Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in
Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or
an implantable cardioverter-defibrillator for congestive heart
failure. N Engl J Med 2005; 352: 225–37.
282 Kadish A, Dyer A, Daubert JP, et al. Defibrillators in NonIschemic Cardiomyopathy Treatment Evaluation (DEFINITE)
Investigators. Prophylactic defibrillator implantation in
patients with nonischemic dilated cardiomyopathy. N Engl J
Med 2004; 350: 2151–8.
283 Clark AL, Goode K, Cleland JG. The prevalence and incidence
of left bundle branch block in ambulant patients with chronic
heart failure. Eur J Heart Fail 2008; 10: 696–702.
© 2009 The European Society of Cardiology
Camm-Chap-23.indd Sec1:9
7/17/2009 3:45:27 PM
THE ESC TEXTBOOK OF CARDIOVASCULAR MEDICINE
284 Bristow MR, Saxon LA, Boehmer J, et al. Comparison of
Medical Therapy, Pacing, and Defibrillation in Heart Failure
(COMPANION) Investigators. Cardiac-resynchronization
therapy with or without an implantable defibrillator in advanced
chronic heart failure. N Engl J Med 2004; 350: 2140–50.
285 Cleland JG, Daubert JC, Erdmann E, et al. Cardiac
Resynchronization-Heart Failure (CARE-HF) Study
Investigators. The effect of cardiac resynchronization on
morbidity and mortality in heart failure. N Engl J Med 2005;
352: 1539–49.
286 Hawkins NM, Petrie MC, Burgess MI, et al. Selecting
patients for cardiac resynchronization therapy: the fallacy of
echocardiographic dyssynchrony. J Am Coll Cardiol 2009; 53:
1944–59.
287 Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors
of Response to CRT (PROSPECT) trial. Circulation 2008; 117:
2608–16.
288 Linde C, Abraham WT, Gold MR, et al. REVERSE
(REsynchronization reVErses Remodeling in Systolic left
vEntricular dysfunction) Study Group. Randomized trial of
cardiac resynchronization in mildly symptomatic heart failure
patients and in symptomatic patients with left ventricular
dysfunction and previous heart failure symptoms. J Am Coll
Cardiol 2008; 52: 1834–43.
289 Beshai JF, Grimm RA, Nagueh SF, et al. RethinQ Study
Investigators. Cardiac-resynchronization therapy in heart
failure with narrow QRS complexes. N Engl J Med 2007; 357:
461–71.
290 Stanton T, Hawkins NM, Hogg KJ, et al. How should we
optimize cardiac resynchronization therapy? Eur Heart J 2008;
29: 2458–72.
291 Rose EA, Gelijns AC, Moskowitz AJ, et al. Randomized
Evaluation of Mechanical Assistance for the Treatment of
Congestive Heart Failure (REMATCH) Study Group.
Long-term mechanical left ventricular assistance for end-stage
heart failure. N Engl J Med 2001; 345: 1435–43.
292 Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass
surgery with or without surgical ventricular reconstruction.
N Engl J Med 2009; 360: 1705–17.
293 Hernandez AF, Shea AM, Milano CA, et al. Long-term
outcomes and costs of ventricular assist devices among
Medicare beneficiaries. JAMA 2008; 300: 2398–406.
294 Lietz K, Miller LW. Destination therapy: current results and
future promise. Semin Thorac Cardiovasc Surg 2008; 20: 225–33.
295 Hiestand BC. Circulatory assist devices in heart failure
patients. Heart Fail Clin 2009; 5: 55–62, vi.
296 Hunt SA, Haddad F. The changing face of heart
transplantation. J Am Coll Cardiol 2008; 52: 587–98.
297 Shah SJ, Gheorghiade M. Heart failure with preserved ejection
fraction: treat now by treating comorbidities. JAMA 2008; 300:
431–3.
298 Hogg K, McMurray J. The treatment of heart failure with
preserved ejection fraction (‘diastolic heart failure’). Heart Fail
Rev 2006; 11: 141–6.
2nd edition
299 Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM Investigators
and Committees. Effects of candesartan in patients with chronic
heart failure and preserved left-ventricular ejection fraction: the
CHARM-Preserved Trial. Lancet 2003; 362: 777–81.
300 Cleland JG, Tendera M, Adamus J, et al. PEP-CHF
Investigators. The perindopril in elderly people with chronic
heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338–45.
301 Massie BM, Carson PE, McMurray JJ, et al. I-PRESERVE
Investigators. Irbesartan in patients with heart failure and
preserved ejection fraction. N Engl J Med 2008; 359: 2456–67.
302 Gray A, Goodacre S, Newby DE, et al. 3CPO Trialists.
Noninvasive ventilation in acute cardiogenic pulmonary
edema. N Engl J Med 2008; 359: 142–51.
303 Ezekowitz JA, Hernandez AF, Starling RC, et al. Standardizing
care for acute decompensated heart failure in a large
megatrial: The approach for the Acute Studies of Clinical
Effectiveness of Nesiritide in Subjects with Decompensated
Heart Failure (ASCEND-HF). Am Heart J 2009; 157: 219–28.
304 Wertman BM, Gura V, Schwarz ER. Ultrafiltration for the
management of acute decompensated heart failure. J Card Fail
2008; 14: 754–9.
305 Elkayam U, Ng TM, Hatamizadeh P, et al. Renal Vasodilatory
Action of Dopamine in Patients With Heart Failure:
Magnitude of Effect and Site of Action. Circulation 2008;
117: 200–5.
306 Fonarow GC, Abraham WT, Albert NM, et al. OPTIMIZE-HF
Investigators and Coordinators. Carvedilol use at discharge
in patients hospitalized for heart failure is associated with
improved survival: an analysis from Organized Program
to Initiate Lifesaving Treatment in Hospitalized Patients
with Heart Failure (OPTIMIZE-HF). Am Heart J 2007;
153: 82.e1–e11.
307 Fonarow GC, Abraham WT, Albert NM, et al. Dosing of betablocker therapy before, during, and after hospitalization for
heart failure (from Organized Program to Initiate Lifesaving
Treatment in Hospitalized Patients with Heart Failure). Am J
Cardiol 2008; 102: 1524–9.
308 Phillips CO, Wright SM, Kern DE, et al. Comprehensive
discharge planning with post discharge support for older
patients with congestive heart failure: a meta-analysis. JAMA
2004; 291: 1358–67.
309 Stewart S, Blue L, Walker A, et al. An economic analysis of
specialist heart failure nurse management in the UK; can we
afford not to implement it? Eur Heart 2002; 23: 1369–78.
310 Stewart S, McMurray JJ. Palliative care for heart failure. BMJ
2002; 325: 915–16.
311 Allen LA, Yager JE, Funk MJ, et al. Discordance between
patient-predicted and model-predicted life expectancy among
ambulatory patients with heart failure. JAMA 2008; 299:
2533–42.
312 Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart
failure: a position statement from the palliative care workshop
of the Heart Failure Association of the European Society of
Cardiology. Eur J Heart Fail 2009; 11: 433–43.
© 2009 The European Society of Cardiology
Camm-Chap-23.indd Sec1:10
7/17/2009 3:45:27 PM